Does Lactobacillus Rhamnosus Improve Gut Health In Individuals With Irritable Bowel Syndrome (IBS)?

Quick answer

Lactobacillus rhamnosus shows some potential benefits for IBS patients, particularly those with diarrhea-predominant IBS, but evidence is limited and mixed. More research is needed to confirm its efficacy.

🔬 What the research shows

A high-quality randomized controlled trial (PMID: 22563194) investigated Lactobacillus casei rhamnosus LCR35 in IBS patients and found no significant improvement in overall IBS severity compared to placebo. However, a subgroup with diarrhea-predominant IBS showed clinically relevant symptom improvement with LCR35. Other studies did not specifically evaluate Lactobacillus rhamnosus alone but used multi-strain probiotics including Lactobacillus species, showing some benefits in IBS symptom management. Meta-analyses and trials on other Lactobacillus strains (not rhamnosus) suggest probiotics may help IBS symptoms generally, but strain-specific effects vary and evidence certainty is often low to moderate. Safety profiles are generally good with few adverse events reported.

Best studied probiotic strains

Lactobacillus casei rhamnosus LCR35

Randomized controlled trial (PMID: 22563194) showed potential benefit in diarrhea-predominant IBS subgroup with clinically relevant symptom improvement, though overall IBS severity improvement was not significant.

Evidence is preliminary and from a small pilot study; larger studies are needed to confirm efficacy.

👥 Who may benefit

IBS patients with diarrhea-predominant subtype

✅ Safety

Lactobacillus rhamnosus LCR35 was well tolerated with no significant adverse events reported. Probiotics in general have a good safety profile in IBS patients, including children and adults, with rare mild adverse events.

⚠️ Limitations

Limited number of studies specifically on Lactobacillus rhamnosus for IBS; small sample sizes in subgroup analyses; mixed results across IBS subtypes; lack of large-scale confirmatory trials; heterogeneity in probiotic strains and formulations; some evidence is low certainty due to risk of bias and inconsistency.